Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A retrotransposable gene l1-fggy and its use as a marker for lung squamous cell carcinoma

A technology of reverse transcription and lung squamous cell carcinoma, which is applied in the field of DNA recombination, can solve the problem of unreported impact on the occurrence and development of lung squamous cell carcinoma, achieve the effect of increasing the ability of cell proliferation and invasion, and promoting the occurrence and development of cells

Active Publication Date: 2021-07-27
TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the replication and transposition of LINE-1 can lead to genetic diseases including tumors, there is no report on its impact on the development of lung squamous cell carcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A retrotransposable gene l1-fggy and its use as a marker for lung squamous cell carcinoma
  • A retrotransposable gene l1-fggy and its use as a marker for lung squamous cell carcinoma
  • A retrotransposable gene l1-fggy and its use as a marker for lung squamous cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0025] 1. Nucleic acid sequence

[0026] L1-FGGY retrotransposable gene sequence:

[0027]

[0028]

[0029] 2. Experimental method

[0030] 1. Clinical Sample Collection

[0031] The present invention collected a total of 110 samples of lung squamous cell carcinoma patients who received partial lung resection from October 2004 to October 2006 in the Department of Lung Oncology. Of the 110 samples of lung squamous cell carcinoma, 52 were collected from their adjacent normal tissues at the same time. The patients included 89 men and 20 women with a median age of 62 years (39-84 years). These patients were all diagnosed as squamous cell carcinoma of the lung, and the clinical stage was stage I in 30 cases, stage II in 34 cases, stage III in 35 cases, and stage IV in 10 cases). No treatment including chemotherapy or radiotherapy was given before...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a retrotransposable gene L1-FGGY and its application as a marker of lung squamous cell carcinoma. The nucleic acid sequence of the retrotransposable gene L1-FGGY is SEQ ID NO.1. The nucleic acid sequence of the upstream detection primer of the retrotransposable gene L1‑FGGY is SEQ ID NO.2; the downstream detection primer nucleic acid sequence is SEQ ID NO.3. The retrotransposition inhibitor nevirapine or efavirenz can inhibit the expression level of the retrotransposition gene L1-FGGY, and is used for the treatment of lung squamous cell carcinoma. The L1‑FGGY retrotransposable gene disclosed in the present invention can be used as a new tumor marker, and the detection of L1‑FGGY can be used for early diagnosis, molecular typing, and prognosis assessment of lung squamous cell carcinoma, while L1‑FGGY It may also become a potential therapeutic target, applied to the clinical treatment of squamous cell carcinoma of the lung, and has broad application prospects.

Description

technical field [0001] The invention relates to DNA recombination technology, more specifically a retrotransposable gene L1-FGGY and its use as a marker of lung squamous cell carcinoma. Background technique [0002] Lung cancer is the most common malignant tumor. Its morbidity and mortality are among the highest in the world. The 5-year survival rate is only about 15.6%. The main reason is that about 75% of patients are diagnosed with advanced lung cancer. Underdiagnosis contributes to the poor prognosis of lung cancer patients. Non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancers, mainly including lung adenocarcinoma, lung squamous cell carcinoma and large cell lung cancer, of which lung squamous cell carcinoma accounts for about 30% of NSCLC. In recent years, the in-depth study of tumor molecular markers such as EGFR and ALK has greatly promoted the molecular diagnosis and targeted therapy of lung adenocarcinoma. However, there is a lack of effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/54A61K31/551A61K31/536A61P35/00
CPCA61K31/536A61K31/551A61P35/00C12N9/1241C12Q1/6886C12Q2600/158
Inventor 于津浦刘芃芃张蕊
Owner TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com